| | Pierce Law - The IP Mall - Resources Hosted by the IP MALL - BPAI - Board of Patent Appeals and Interferences - ... |
 | | The Rejection Under 35 U.S.C. The rejection under 35 U.S.C. 103 is based upon the examiner's determination that the Abstract discloses unit dosages of diethylhydroxylamine in water for the treatment of cancer in mice, which unit dosages correspond to the unit dosages encompassed by the rejected claims. |
 | | Assuming, arguendo, the increased longevity was due directly or indirectly to the administration of diethylhydroxylamine, there is insufficient evidence upon which to conclude that the increased longevity resulted from a retardation of the aging process caused by diethylhydroxylamine. |
 | | Appellant has not advanced any cogent reasoning or proffered evidence to support the conclusion that the results obtained with mice can reasonably be extrapolated to the other animals encompassed by the appealed claims, such as cattle, or to the other compounds encompassed by claims 1 through 5, 7, 8, 10 through 17 and 19. |
| www.ipmall.fplc.edu /hosted_resources/BPAI_Decisions/BPAI_Appeal_88-0953.asp (1508 words) |